A Phase III multi-centre randomised controlled trial to assess whether optimal supportive care alone (including Dexamethasone ) is as effective as optimal supportive care (including Dexamethasone) plus whole brain radiotherapy in the treatment of patients with inoperable brain metastases from non-small cell lung cancer.

Primary Sponsor

Clinical Trial Registration

Related Post

31 March, 2026

TROG Secondary Data Analysis Grant awarded to project to better understand prostate cancer therapy outcomes

LATEST NEWS: 31 March 2026 TROG’s inaugural Secondary Data

26 March, 2026

TROG welcomes new Board members and President-Elect

LATEST NEWS: 26 March 2026 We are delighted to